Drugmakers face conflict over IP protections in trans-Pacific trade talks

07/21/2013 | Financial Times (tiered subscription model)

Drug-development groups and drugmakers are in disagreement over intellectual property provisions in the Trans-Pacific Partnership negotiations. An open letter was issued last week by the international charity Doctors Without Borders expressing major concern about the TPP's potential to curb access to drugs. The Pharmaceutical Research and Manufacturers of America wants to use TPP talks to raise IP standards to U.S. levels, arguing that IP protections won't block access but provide an incentive for investments. "Strong intellectual property protections in the TPP to bolster biopharmaceutical innovation will help ensure that unmet patient needs are addressed," PhRMA said.

View Full Article in:

Financial Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ